Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNV3 plus toripalimab in relapsed or metastatic rare skin neoplasms
ChiCTR2400094556Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of DNV3 and toripalimab in cutaneous neoplasm, cutaneous angiosarcoma, cutaneous squamous cell carcinoma (cSCC) and 4 more (7 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Safety and tolerability and Objective response rate. Started Dec 2024; status: completed.
02
Drugs
DNV3toripalimab
03
Conditions
cutaneous neoplasmcutaneous angiosarcomacutaneous squamous cell carcinoma (cSCC)melanomaCutaneous sweat gland ductal carcinoma
Beyond the preview
Go deeper on ChiCTR2400094556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094556.